{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:09:24Z","timestamp":1790050164150,"version":"4.0.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Drexel Coulter Translational fund"},{"name":"Drexel University Medical student summer research fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson\u2019s disease (PD) is a systemic disease characterized by motor and nonmotor impairments. Loss of dopaminergic neurons in the substantia nigra pars compacta region in PD disrupts dopamine-glutamate homeostasis in the corticostriatal circuit, contributing to cognitive impairment. In addition, excitatory amino acid transporter-2 (EAAT2), localized predominantly to astrocytes and responsible for\u2009&gt;\u200980% of synaptic glutamate clearance, is downregulated in PD, causing glutamate spillover and excitotoxicity. This altered dopamine-glutamate homeostasis and excitotoxicity may affect reward-mediated decision-making behaviors and promote impulsive behaviors in PD. In this study, we hypothesized that GTS467, a small-molecule activator of EAAT2, could effectively reduce excitotoxicity and treat cognitive impairment without promoting impulsive behavior in PD. Rats that were unilaterally lesioned with the 6-OHDA toxin to produce Parkinsonian symptoms were referred to as lesioned rats. Lesioned rats were trained to meet baseline criteria in a 5-choice serial reaction time task, and the chronic effects of GTS467 were assessed after 3\u00a0weeks of treatment. The results showed that chronic treatment with GTS467 significantly improved correct responses and reduced premature impulsive responses and omissions compared with saline treatment. This improvement in performance correlated with a reduction in glutamate levels, an increase in EAAT2 expression, and normalization of NMDA receptor subunit expression and signaling. Furthermore, transcriptomic studies on the prefrontal cortex tissue have shown the differential expression of genes involved in neuroprotection, neuroinflammation, learning, and memory. These results validate the role of glutamate excitotoxicity in promoting impulsive behaviors and suggest that GTS467 can be developed as a therapeutic agent to reduce cognitive impairment and impulsive behaviors in PD.<\/jats:p>","DOI":"10.1007\/s12035-024-04644-0","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T08:37:53Z","timestamp":1733301473000},"page":"5787-5803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["EAAT2 Activation Regulates Glutamate Excitotoxicity and Reduces Impulsivity in a Rodent Model of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"62","author":[{"given":"Sanjay","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Mccloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Nepal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Kortagere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"10","key":"4644_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12(10):366\u2013375","journal-title":"Trends Neurosci"},{"issue":"1","key":"4644_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0301-0082(99)00067-2","volume":"62","author":"F Blandini","year":"2000","unstructured":"Blandini F et al (2000) Functional changes of the basal ganglia circuitry in Parkinson\u2019s disease. Prog Neurobiol 62(1):63\u201388","journal-title":"Prog Neurobiol"},{"issue":"2","key":"4644_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF00419650","volume":"55","author":"JG Phillips","year":"1993","unstructured":"Phillips JG et al (1993) Motor functions of the basal ganglia. Psychol Res 55(2):175\u2013181","journal-title":"Psychol Res"},{"key":"4644_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0404.1991.tb05026.x","volume":"136","author":"JO Rinne","year":"1991","unstructured":"Rinne JO (1991) Nigral degeneration in Parkinson\u2019s disease in relation to clinical features. Acta Neurol Scand Suppl 136:87\u201390","journal-title":"Acta Neurol Scand Suppl"},{"issue":"1","key":"4644_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ptj\/71.1.60","volume":"71","author":"GE Stelmach","year":"1991","unstructured":"Stelmach GE, Phillips JG (1991) Movement disorders\u2013limb movement and the basal ganglia. Phys Ther 71(1):60\u201367","journal-title":"Phys Ther"},{"key":"4644_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","volume":"90","author":"J Pagonabarraga","year":"2021","unstructured":"Pagonabarraga J et al (2021) The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: Clinical cases and a review of the literature. J Clin Neurosci 90:178\u2013183","journal-title":"J Clin Neurosci"},{"issue":"7","key":"4644_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435\u2013450","journal-title":"Nat Rev Neurosci"},{"issue":"S3","key":"4644_CR8","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26(S3):S42-80","journal-title":"Mov Disord"},{"key":"4644_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108880","volume":"203","author":"JS Schneider","year":"2022","unstructured":"Schneider JS, Kortagere S (2022) Current concepts in treating mild cognitive impairment in Parkinson\u2019s disease. Neuropharmacology 203:108880","journal-title":"Neuropharmacology"},{"issue":"2","key":"4644_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1360-0443.2010.03218.x","volume":"106","author":"P Ambermoon","year":"2011","unstructured":"Ambermoon P et al (2011) Impulse control disorders in patients with Parkinson\u2019s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106(2):283\u2013293","journal-title":"Addiction"},{"issue":"4","key":"4644_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cpr.2006.01.001","volume":"26","author":"CA Winstanley","year":"2006","unstructured":"Winstanley CA, Eagle DM, Robbins TW (2006) Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev 26(4):379\u2013395","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"4644_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/cercor\/bhi088","volume":"16","author":"CA Winstanley","year":"2006","unstructured":"Winstanley CA et al (2006) Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice. Cereb Cortex 16(1):106\u2013114","journal-title":"Cereb Cortex"},{"issue":"4","key":"4644_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1037\/a0023795","volume":"125","author":"DO Claassen","year":"2011","unstructured":"Claassen DO et al (2011) The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci 125(4):492\u2013500","journal-title":"Behav Neurosci"},{"issue":"18","key":"4644_CR14","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1523\/JNEUROSCI.5253-10.2011","volume":"31","author":"S Jahfari","year":"2011","unstructured":"Jahfari S et al (2011) Effective connectivity reveals important roles for both the hyperdirect (fronto-subthalamic) and the indirect (fronto-striatal-pallidal) fronto-basal ganglia pathways during response inhibition. J Neurosci 31(18):6891\u20136899","journal-title":"J Neurosci"},{"issue":"2","key":"4644_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1162\/jocn.2010.21444","volume":"23","author":"S van Gaal","year":"2011","unstructured":"van Gaal S et al (2011) Pre-SMA graymatter density predicts individual differences in action selection in the face of conscious and unconscious response conflict. J Cogn Neurosci 23(2):382\u2013390","journal-title":"J Cogn Neurosci"},{"issue":"11","key":"4644_CR16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH et al (2009) Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord 24(11):1561\u20131570","journal-title":"Mov Disord"},{"key":"4644_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cortex.2023.10.008","volume":"171","author":"G Mattavelli","year":"2024","unstructured":"Mattavelli G et al (2024) Cognitive and motor impulsivity in the healthy brain, and implications for eating disorders and obesity: A coordinate-based meta-analysis and systematic review. Cortex 171:90\u2013112","journal-title":"Cortex"},{"issue":"9","key":"4644_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.euroneuro.2015.07.012","volume":"25","author":"EM Pich","year":"2015","unstructured":"Pich EM, Collo G (2015) Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. Eur Neuropsychopharmacol 25(9):1437\u20131447","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"4644_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","volume":"63","author":"D Weintraub","year":"2006","unstructured":"Weintraub D et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63(7):969\u2013973","journal-title":"Arch Neurol"},{"issue":"3","key":"4644_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: The role of glial cells. J Pharmacol Sci 144(3):151\u2013164","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"4644_CR21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1046\/j.1460-9568.1999.00627.x","volume":"11","author":"E Bezard","year":"1999","unstructured":"Bezard E et al (1999) Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur J Neurosci 11(6):2167\u20132170","journal-title":"Eur J Neurosci"},{"issue":"33","key":"4644_CR22","doi-asserted-by":"publisher","first-page":"34388","DOI":"10.1074\/jbc.M403938200","volume":"279","author":"ME Butchbach","year":"2004","unstructured":"Butchbach ME et al (2004) Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem 279(33):34388\u201334396","journal-title":"J Biol Chem"},{"issue":"3","key":"4644_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0896-6273(94)90038-8","volume":"13","author":"JD Rothstein","year":"1994","unstructured":"Rothstein JD et al (1994) Localization of neuronal and glial glutamate transporters. Neuron 13(3):713\u2013725","journal-title":"Neuron"},{"key":"4644_CR24","doi-asserted-by":"publisher","first-page":"II36","DOI":"10.1007\/PL00007759","volume":"247","author":"TN Chase","year":"2000","unstructured":"Chase TN, Oh JD, Konitsiotis S (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 247:II36\u2013II42","journal-title":"J Neurol"},{"issue":"2","key":"4644_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","volume":"229","author":"KB Dupre","year":"2011","unstructured":"Dupre KB et al (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229(2):288\u2013299","journal-title":"Exp Neurol"},{"issue":"2","key":"4644_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/syn.10291","volume":"51","author":"C Marin","year":"2004","unstructured":"Marin C et al (2004) Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse 51(2):140\u2013150","journal-title":"Synapse"},{"issue":"1","key":"4644_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1523\/JNEUROSCI.20-01-00022.2000","volume":"20","author":"R Sattler","year":"2000","unstructured":"Sattler R et al (2000) Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J Neurosci 20(1):22\u201333","journal-title":"J Neurosci"},{"issue":"24","key":"4644_CR28","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1073\/pnas.0903546106","volume":"106","author":"RI Stanika","year":"2009","unstructured":"Stanika RI et al (2009) Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A 106(24):9854\u20139859","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4644_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02740748","volume":"12","author":"F Blandini","year":"1996","unstructured":"Blandini F, Porter RH, Greenamyre JT (1996) Glutamate and Parkinson\u2019s disease. Mol Neurobiol 12(1):73\u201394","journal-title":"Mol Neurobiol"},{"issue":"4975","key":"4644_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2402638","volume":"249","author":"H Bergman","year":"1990","unstructured":"Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249(4975):1436\u20131438","journal-title":"Science"},{"issue":"16","key":"4644_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM199810153391603","volume":"339","author":"P Limousin","year":"1998","unstructured":"Limousin P et al (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N Engl J Med 339(16):1105\u20131111","journal-title":"N Engl J Med"},{"issue":"Pt 8","key":"4644_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/brain\/awm137","volume":"130","author":"BA Wallace","year":"2007","unstructured":"Wallace BA et al (2007) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130(Pt 8):2129\u20132145","journal-title":"Brain"},{"issue":"2","key":"4644_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JPD-191841","volume":"10","author":"CM Tanner","year":"2020","unstructured":"Tanner CM et al (2020) EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson\u2019s Disease. J Parkinsons Dis 10(2):543\u2013558","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"4644_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0028-3908(03)00146-1","volume":"45","author":"G Battaglia","year":"2003","unstructured":"Battaglia G et al (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45(2):155\u2013166","journal-title":"Neuropharmacology"},{"issue":"10","key":"4644_CR35","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mds.27462","volume":"33","author":"D Charvin","year":"2018","unstructured":"Charvin D et al (2018) An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. Mov Disord 33(10):1619\u20131631","journal-title":"Mov Disord"},{"issue":"6","key":"4644_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.410350605","volume":"35","author":"JT Greenamyre","year":"1994","unstructured":"Greenamyre JT et al (1994) Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson\u2019s disease. Ann Neurol 35(6):655\u2013661","journal-title":"Ann Neurol"},{"issue":"4","key":"4644_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0028-3908(01)00083-1","volume":"41","author":"K Ossowska","year":"2001","unstructured":"Ossowska K et al (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41(4):413\u2013420","journal-title":"Neuropharmacology"},{"issue":"7","key":"4644_CR38","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1007\/s12035-018-1433-x","volume":"56","author":"L Pagliaroli","year":"2019","unstructured":"Pagliaroli L et al (2019) Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model. Mol Neurobiol 56(7):5111\u20135121","journal-title":"Mol Neurobiol"},{"issue":"2\u20133","key":"4644_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF02251229","volume":"10","author":"MS Starr","year":"1995","unstructured":"Starr MS (1995) Antiparkinsonian actions of glutamate antagonists\u2013alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm Park Dis Dement Sect 10(2\u20133):141\u2013185","journal-title":"J Neural Transm Park Dis Dement Sect"},{"issue":"1","key":"4644_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","volume":"65","author":"NC Danbolt","year":"2001","unstructured":"Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65(1):1\u2013105","journal-title":"Prog Neurobiol"},{"issue":"5","key":"4644_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.410400512","volume":"40","author":"E Masliah","year":"1996","unstructured":"Masliah E et al (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer\u2019s disease. Ann Neurol 40(5):759\u2013766","journal-title":"Ann Neurol"},{"issue":"14","key":"4644_CR42","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1073\/pnas.90.14.6591","volume":"90","author":"JD Rothstein","year":"1993","unstructured":"Rothstein JD et al (1993) Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 90(14):6591\u20136595","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4644_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410380114","volume":"38","author":"JD Rothstein","year":"1995","unstructured":"Rothstein JD et al (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38(1):73\u201384","journal-title":"Ann Neurol"},{"issue":"4","key":"4644_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pneurobio.2007.10.010","volume":"84","author":"MM Acharya","year":"2008","unstructured":"Acharya MM, Hattiangady B, Shetty AK (2008) Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 84(4):363\u2013404","journal-title":"Prog Neurobiol"},{"issue":"4693","key":"4644_CR45","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1126\/science.2858129","volume":"227","author":"JT Greenamyre","year":"1985","unstructured":"Greenamyre JT et al (1985) Alterations in L-glutamate binding in Alzheimer\u2019s and Huntington\u2019s diseases. Science 227(4693):1496\u20131499","journal-title":"Science"},{"issue":"5319","key":"4644_CR46","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1126\/science.276.5319.1699","volume":"276","author":"K Tanaka","year":"1997","unstructured":"Tanaka K et al (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276(5319):1699\u20131702","journal-title":"Science"},{"issue":"11\u201312","key":"4644_CR47","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbadis.2006.05.002","volume":"1762","author":"L Van Den Bosch","year":"2006","unstructured":"Van Den Bosch L et al (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762(11\u201312):1068\u20131082","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"4644_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061177","volume":"8","author":"JD Berry","year":"2013","unstructured":"Berry JD et al (2013) Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE 8(4):e61177","journal-title":"PLoS ONE"},{"issue":"7021","key":"4644_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein JD et al (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433(7021):73\u201377","journal-title":"Nature"},{"issue":"3","key":"4644_CR50","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1172\/JCI66163","volume":"124","author":"Q Kong","year":"2014","unstructured":"Kong Q et al (2014) Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest 124(3):1255\u20131267","journal-title":"J Clin Invest"},{"issue":"3","key":"4644_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1084\/jem.20140413","volume":"212","author":"K Takahashi","year":"2015","unstructured":"Takahashi K et al (2015) Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer\u2019s disease. J Exp Med 212(3):319\u2013332","journal-title":"J Exp Med"},{"issue":"3","key":"4644_CR52","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1021\/acschemneuro.9b00609","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) Generation of a Novel Mouse Model of Parkinson\u2019s Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra. ACS Chem Neurosci 11(3):406\u2013417","journal-title":"ACS Chem Neurosci"},{"key":"4644_CR53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fncel.2014.00301","volume":"8","author":"DA Beccano-Kelly","year":"2014","unstructured":"Beccano-Kelly DA et al (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 8:301","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"4644_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191670","volume":"13","author":"M Figura","year":"2018","unstructured":"Figura M et al (2018) Serum amino acid profile in patients with Parkinson\u2019s disease. PLoS ONE 13(1):e0191670","journal-title":"PLoS ONE"},{"issue":"1","key":"4644_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0306-4522(98)00189-4","volume":"88","author":"CK Meshul","year":"1999","unstructured":"Meshul CK et al (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88(1):1\u201316","journal-title":"Neuroscience"},{"issue":"5321","key":"4644_CR56","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276(5321):2045\u20132047","journal-title":"Science"},{"issue":"3\u20134","key":"4644_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","volume":"11","author":"N Simola","year":"2007","unstructured":"Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson\u2019s disease. Neurotox Res 11(3\u20134):151\u2013167","journal-title":"Neurotox Res"},{"issue":"3","key":"4644_CR58","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1471-4159.2007.04860.x","volume":"103","author":"AC Vernon","year":"2007","unstructured":"Vernon AC et al (2007) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 103(3):1075\u20131091","journal-title":"J Neurochem"},{"key":"4644_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.03.002","volume":"161","author":"E Pajarillo","year":"2019","unstructured":"Pajarillo E et al (2019) The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics. Neuropharmacology 161:107559","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"4644_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.schres.2008.06.012","volume":"104","author":"D Bauer","year":"2008","unstructured":"Bauer D et al (2008) Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 104(1\u20133):108\u2013120","journal-title":"Schizophr Res"},{"issue":"4","key":"4644_CR61","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1471-4159.2006.03629.x","volume":"97","author":"C Boehmer","year":"2006","unstructured":"Boehmer C et al (2006) Post-translational regulation of EAAT2 function by co-expressed ubiquitin ligase Nedd4-2 is impacted by SGK kinases. J Neurochem 97(4):911\u2013921","journal-title":"J Neurochem"},{"issue":"2","key":"4644_CR62","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cercor\/8.2.108","volume":"8","author":"F Conti","year":"1998","unstructured":"Conti F et al (1998) EAAC1, a high-affinity glutamate tranporter, is localized to astrocytes and gabaergic neurons besides pyramidal cells in the rat cerebral cortex. Cereb Cortex 8(2):108\u2013116","journal-title":"Cereb Cortex"},{"issue":"3 Pt 1","key":"4644_CR63","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1523\/JNEUROSCI.15-03-01835.1995","volume":"15","author":"KP Lehre","year":"1995","unstructured":"Lehre KP et al (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J Neurosci 15(3 Pt 1):1835\u20131853","journal-title":"J Neurosci"},{"issue":"3","key":"4644_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/glia.20119","volume":"49","author":"C Matute","year":"2005","unstructured":"Matute C et al (2005) Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49(3):451\u2013455","journal-title":"Glia"},{"issue":"1","key":"4644_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.12697","volume":"130","author":"PJ Vollbrecht","year":"2014","unstructured":"Vollbrecht PJ et al (2014) Dopamine denervation of the prefrontal cortex increases expression of the astrocytic glutamate transporter GLT-1. J Neurochem 130(1):109\u2013114","journal-title":"J Neurochem"},{"issue":"10","key":"4644_CR66","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1021\/acsmedchemlett.2c00304","volume":"13","author":"S Das","year":"2022","unstructured":"Das S et al (2022) Design and Characterization of Novel Small Molecule Activators of Excitatory Amino Acid Transporter 2. ACS Med Chem Lett 13(10):1628\u20131633","journal-title":"ACS Med Chem Lett"},{"key":"4644_CR67","doi-asserted-by":"publisher","first-page":"1176777","DOI":"10.3389\/fnbeh.2023.1176777","volume":"17","author":"A Bhatnagar","year":"2023","unstructured":"Bhatnagar A et al (2023) Novel EAAT2 activators improve motor and cognitive impairment in a transgenic model of Huntington\u2019s disease. Front Behav Neurosci 17:1176777","journal-title":"Front Behav Neurosci"},{"key":"4644_CR68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuropharm.2015.04.004","volume":"100","author":"SL Simms","year":"2016","unstructured":"Simms SL, Huettner DP, Kortagere S (2016) In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson\u2019s disease. Neuropharmacology 100:106\u2013115","journal-title":"Neuropharmacology"},{"key":"4644_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113514","volume":"335","author":"JS Schneider","year":"2021","unstructured":"Schneider JS et al (2021) A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson\u2019s disease. Exp Neurol 335:113514","journal-title":"Exp Neurol"},{"issue":"4","key":"4644_CR70","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41386-020-00879-2","volume":"46","author":"IP Alonso","year":"2021","unstructured":"Alonso IP et al (2021) Dopamine transporter function fluctuates across sleep\/wake state: potential impact for addiction. Neuropsychopharmacology 46(4):699\u2013708","journal-title":"Neuropsychopharmacology"},{"key":"4644_CR71","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.addicn.2023.100104","volume":"7","author":"EM Black","year":"2023","unstructured":"Black EM et al (2023) Hypocretin \/ Orexin Receptor 1 Knockdown in GABA or Dopamine Neurons in the Ventral Tegmental Area Differentially Impact Mesolimbic Dopamine and Motivation for Cocaine. Addict Neurosci 7:100104","journal-title":"Addict Neurosci"},{"issue":"45","key":"4644_CR72","doi-asserted-by":"publisher","first-page":"8767","DOI":"10.1523\/JNEUROSCI.0894-20.2020","volume":"40","author":"ZD Brodnik","year":"2020","unstructured":"Brodnik ZD et al (2020) Chemogenetic Manipulation of Dopamine Neurons Dictates Cocaine Potency at Distal Dopamine Transporters. J Neurosci 40(45):8767\u20138779","journal-title":"J Neurosci"},{"issue":"6","key":"4644_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13241","volume":"27","author":"KR Samson","year":"2022","unstructured":"Samson KR et al (2022) Intermittent access to oxycodone decreases dopamine uptake in the nucleus accumbens core during abstinence. Addict Biol 27(6):e13241","journal-title":"Addict Biol"},{"issue":"1","key":"4644_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12974-022-02542-7","volume":"19","author":"H Sun","year":"2022","unstructured":"Sun H et al (2022) Drp1 activates ROS\/HIF-1alpha\/EZH2 and triggers mitochondrial fragmentation to deteriorate hypercalcemia-associated neuronal injury in mouse model of chronic kidney disease. J Neuroinflammation 19(1):213","journal-title":"J Neuroinflammation"},{"issue":"4","key":"4644_CR75","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R et al (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14(4):417\u2013419","journal-title":"Nat Methods"},{"key":"4644_CR76","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson C, Love MI, Robinson MD (2015) Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4:1521","journal-title":"F1000Res"},{"issue":"12","key":"4644_CR77","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550","journal-title":"Genome Biol"},{"issue":"1\u20132","key":"4644_CR78","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y et al (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1\u20132):279\u2013284","journal-title":"Behav Brain Res"},{"issue":"1\u20132","key":"4644_CR79","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0006-8993(96)00915-8","volume":"741","author":"M Gerlach","year":"1996","unstructured":"Gerlach M et al (1996) A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 741(1\u20132):142\u2013152","journal-title":"Brain Res"},{"issue":"1","key":"4644_CR80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.expneurol.2010.09.001","volume":"226","author":"AC Lanoue","year":"2010","unstructured":"Lanoue AC et al (2010) Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson\u2019s disease. Exp Neurol 226(1):207\u2013217","journal-title":"Exp Neurol"},{"issue":"Pt 2","key":"4644_CR81","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/brain\/108.2.301","volume":"108","author":"JC Monfort","year":"1985","unstructured":"Monfort JC et al (1985) Brain glutamate decarboxylase in Parkinson\u2019s disease with particular reference to a premortem severity index. Brain 108(Pt 2):301\u2013313","journal-title":"Brain"},{"issue":"3","key":"4644_CR82","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1254\/jjp.48.331","volume":"48","author":"N Nishino","year":"1988","unstructured":"Nishino N et al (1988) GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson\u2019s disease. Jpn J Pharmacol 48(3):331\u2013339","journal-title":"Jpn J Pharmacol"},{"issue":"5","key":"4644_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0361-9230(99)00258-0","volume":"52","author":"JM Fuster","year":"2000","unstructured":"Fuster JM (2000) Prefrontal neurons in networks of executive memory. Brain Res Bull 52(5):331\u2013336","journal-title":"Brain Res Bull"},{"issue":"3","key":"4644_CR84","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0896-6273(95)90304-6","volume":"14","author":"PS Goldman-Rakic","year":"1995","unstructured":"Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron 14(3):477\u2013485","journal-title":"Neuron"},{"issue":"15","key":"4644_CR85","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1523\/JNEUROSCI.23-15-06351.2003","volume":"23","author":"SJ Lewis","year":"2003","unstructured":"Lewis SJ et al (2003) Cognitive impairments in early Parkinson\u2019s disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23(15):6351\u20136356","journal-title":"J Neurosci"},{"issue":"1","key":"4644_CR86","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s002210100839","volume":"141","author":"M Pierantozzi","year":"2001","unstructured":"Pierantozzi M et al (2001) Effect of apomorphine on cortical inhibition in Parkinson\u2019s disease patients: a transcranial magnetic stimulation study. Exp Brain Res 141(1):52\u201362","journal-title":"Exp Brain Res"},{"issue":"2","key":"4644_CR87","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.410370208","volume":"37","author":"MC Ridding","year":"1995","unstructured":"Ridding MC, Inzelberg R, Rothwell JC (1995) Changes in excitability of motor cortical circuitry in patients with Parkinson\u2019s disease. Ann Neurol 37(2):181\u2013188","journal-title":"Ann Neurol"},{"issue":"6","key":"4644_CR88","first-page":"725","volume":"43","author":"S Sestini","year":"2002","unstructured":"Sestini S et al (2002) Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson\u2019s disease. J Nucl Med 43(6):725\u2013732","journal-title":"J Nucl Med"},{"issue":"6","key":"4644_CR89","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.neuron.2012.12.002","volume":"76","author":"DR Euston","year":"2012","unstructured":"Euston DR, Gruber AJ, McNaughton BL (2012) The role of medial prefrontal cortex in memory and decision making. Neuron 76(6):1057\u20131070","journal-title":"Neuron"},{"issue":"2","key":"4644_CR90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tics.2010.12.004","volume":"15","author":"F Grabenhorst","year":"2011","unstructured":"Grabenhorst F, Rolls ET (2011) Value, pleasure and choice in the ventral prefrontal cortex. Trends Cogn Sci 15(2):56\u201367","journal-title":"Trends Cogn Sci"},{"issue":"6","key":"4644_CR91","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","volume":"51","author":"JH Patton","year":"1995","unstructured":"Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51(6):768\u2013774","journal-title":"J Clin Psychol"},{"issue":"4","key":"4644_CR92","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40429-014-0036-5","volume":"1","author":"V Voon","year":"2014","unstructured":"Voon V (2014) Models of Impulsivity with a Focus on Waiting Impulsivity: Translational Potential for Neuropsychiatric Disorders. Curr Addict Rep 1(4):281\u2013288","journal-title":"Curr Addict Rep"},{"issue":"6","key":"4644_CR93","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1037\/a0033659","volume":"21","author":"J Weafer","year":"2013","unstructured":"Weafer J, Baggott MJ, de Wit H (2013) Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention. Exp Clin Psychopharmacol 21(6):475\u2013481","journal-title":"Exp Clin Psychopharmacol"},{"key":"4644_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.654238","volume":"15","author":"A Augustine","year":"2021","unstructured":"Augustine A, Winstanley CA, Krishnan V (2021) Impulse Control Disorders in Parkinson\u2019s Disease: From Bench to Bedside. Front Neurosci 15:654238","journal-title":"Front Neurosci"},{"key":"4644_CR95","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pneurobio.2013.06.005","volume":"108","author":"A Bari","year":"2013","unstructured":"Bari A, Robbins TW (2013) Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol 108:44\u201379","journal-title":"Prog Neurobiol"},{"issue":"5","key":"4644_CR96","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nprot.2008.41","volume":"3","author":"A Bari","year":"2008","unstructured":"Bari A, Dalley JW, Robbins TW (2008) The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 3(5):759\u2013767","journal-title":"Nat Protoc"},{"issue":"1","key":"4644_CR97","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.expneurol.2009.06.005","volume":"219","author":"GE Meredith","year":"2009","unstructured":"Meredith GE et al (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson\u2019s disease. Exp Neurol 219(1):334\u2013340","journal-title":"Exp Neurol"},{"issue":"1","key":"4644_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0014-4886(02)00050-X","volume":"180","author":"S Robinson","year":"2003","unstructured":"Robinson S et al (2003) Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 180(1):74\u201387","journal-title":"Exp Neurol"},{"issue":"52","key":"4644_CR99","doi-asserted-by":"publisher","first-page":"20953","DOI":"10.1073\/pnas.0811025106","volume":"105","author":"GM Elias","year":"2008","unstructured":"Elias GM et al (2008) Differential trafficking of AMPA and NMDA receptors by SAP102 and PSD-95 underlies synapse development. Proc Natl Acad Sci U S A 105(52):20953\u201320958","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4644_CR100","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.nbd.2007.10.003","volume":"29","author":"JF Torres-Peraza","year":"2008","unstructured":"Torres-Peraza JF et al (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol Dis 29(3):409\u2013421","journal-title":"Neurobiol Dis"},{"issue":"8","key":"4644_CR101","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1074\/jbc.M114.599969","volume":"290","author":"Z Wei","year":"2015","unstructured":"Wei Z et al (2015) Subunit-specific regulation of N-methyl-D-aspartate (NMDA) receptor trafficking by SAP102 protein splice variants. J Biol Chem 290(8):5105\u20135116","journal-title":"J Biol Chem"},{"key":"4644_CR102","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bcp.2019.07.007","volume":"168","author":"BD Davis-Reyes","year":"2019","unstructured":"Davis-Reyes BD et al (2019) Profile of cortical N-methyl-D-aspartate receptor subunit expression associates with inherent motor impulsivity in rats. Biochem Pharmacol 168:204\u2013213","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4644_CR103","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1152\/jn.00998.2007","volume":"99","author":"S Ramanathan","year":"2008","unstructured":"Ramanathan S et al (2008) D2-like dopamine receptors modulate SKCa channel function in subthalamic nucleus neurons through inhibition of Cav2.2 channels. J Neurophysiol 99(2):442\u201359","journal-title":"J Neurophysiol"},{"issue":"17","key":"4644_CR104","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/1873-3468.13853","volume":"594","author":"H Saegusa","year":"2020","unstructured":"Saegusa H et al (2020) Knockdown of microglial Cav2.2 N-type voltage-dependent Ca(2+) channel ameliorates behavioral deficits in a mouse model of Parkinson\u2019s disease. FEBS Lett 594(17):2914\u20132922","journal-title":"FEBS Lett"},{"issue":"6","key":"4644_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199189","volume":"13","author":"JS Schneider","year":"2018","unstructured":"Schneider JS (2018) Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson\u2019s disease. PLoS ONE 13(6):e0199189","journal-title":"PLoS ONE"},{"key":"4644_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mcn.2019.01.001","volume":"95","author":"M Verma","year":"2019","unstructured":"Verma M, Schneider JS (2019) siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration. Mol Cell Neurosci 95:25\u201330","journal-title":"Mol Cell Neurosci"},{"key":"4644_CR107","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fneur.2019.00859","volume":"10","author":"PJ Magistretti","year":"2019","unstructured":"Magistretti PJ et al (2019) Gangliosides: Treatment Avenues in Neurodegenerative Disease. Front Neurol 10:859","journal-title":"Front Neurol"},{"issue":"11","key":"4644_CR108","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.3390\/ijms24119183","volume":"24","author":"JS Schneider","year":"2023","unstructured":"Schneider JS (2023) GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson\u2019s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson\u2019s Disease-Relevant Pathogenic Mechanisms. Int J Mol Sci 24(11):9183","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4644_CR109","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1038\/s41598-019-42847-x","volume":"9","author":"JS Schneider","year":"2019","unstructured":"Schneider JS et al (2019) GM1 Ganglioside Modifies alpha-Synuclein Toxicity and is Neuroprotective in a Rat alpha-Synuclein Model of Parkinson\u2019s Disease. Sci Rep 9(1):8362","journal-title":"Sci Rep"},{"key":"4644_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2022.103729","volume":"120","author":"JS Schneider","year":"2022","unstructured":"Schneider JS et al (2022) GM1 ganglioside modifies microglial and neuroinflammatory responses to alpha-synuclein in the rat AAV-A53T alpha-synuclein model of Parkinson\u2019s disease. Mol Cell Neurosci 120:103729","journal-title":"Mol Cell Neurosci"},{"key":"4644_CR111","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1196\/annals.1418.013","volume":"1144","author":"A HalabeBucay","year":"2008","unstructured":"HalabeBucay A (2008) Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson\u2019s disease: a new hypothesis. Ann N Y Acad Sci 1144:237\u2013242","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"4644_CR112","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.220098","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y et al (2022) TRIM family proteins: roles in proteostasis and neurodegenerative diseases. Open Biol 12(8):220098","journal-title":"Open Biol"},{"key":"4644_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110689","volume":"108","author":"A Zorn","year":"2023","unstructured":"Zorn A, Baillie G (2023) Phosphodiesterase 7 as a therapeutic target - Where are we now? Cell Signal 108:110689","journal-title":"Cell Signal"},{"issue":"3","key":"4644_CR114","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.celrep.2017.06.072","volume":"20","author":"C Kerimoglu","year":"2017","unstructured":"Kerimoglu C et al (2017) KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions. Cell Rep 20(3):538\u2013548","journal-title":"Cell Rep"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04644-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T23:50:46Z","timestamp":1743551446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04644-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4644"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04644-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of Drexel University and were conducted in compliance with government regulations including the Animal Welfare Act and the Public Health Service Policy on Humane Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors consented to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors read the manuscript and have consented for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.\u00a0GTS467 has been submitted as part of the patent application No. PCT\/US23\/11385, filed on January 24, 2023 and SK is named inventor on the application.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}